8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

April 10, 2013

(Date of the earliest event reported)

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

California	001-32046	95-4595609
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

42505 10^th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

661-723-7723

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Item 8.01       Other Events

On April 10, 2013, Simulations Plus, Inc., a California corporation (the "Company"), held a conference call reporting its financial result for the second fiscal quarter ended February 28, 2013.

The press release and the PowerPoint slides, which were used for this Conference Call, are attached herein as exhibits.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01       Financial Statements and Exhibits

(d)       Exhibits

99.1       Press Release

99.2       PowerPoint presentation at the Conference Call on April 10, 2013.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SIMULATIONS PLUS, INC.
Dated: April 10, 2013	By: /s/ Momoko Beran
	Momoko Beran
	Chief Financial Officer

2

EX-99.1

Exhibit 99.1

SimulationsPlus

Integrating Science and Software

For Further Information:

Simulations Plus, Inc.

42505 10^th Street West

Lancaster, CA 93534-7059

CONTACT:

Simulations Plus Investor Relations	Hayden IR
Ms. Renée Bouché	Mr. Cameron Donahue
661-723-7723	651-653-1854
renee@simulations-plus.com	cameron@haydenir.com

For Immediate Release:

April 10, 2013

Simulations Plus Reports Second Quarter and First Six Months FY2013 Financial Results

Second quarter net sales increase 11.8%; net income up 26.5%

LANCASTER, CA, April 10, 2013 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2013 ended February 28, 2013 (2QFY13).

2QFY13 highlights compared with 2QFY12:

· Net sales increased 11.8% to new record for any quarter of $3.118 million from $2.789 million

· This was the Company’s 22^nd consecutive profitable quarter, and the 44^th of the last 46 quarters

· Gross profit increased 9.5% to $2.619 million from $2.393 million

· SG&A decreased 10.6% to $0.855 million from $0.956 million

o As a percent of revenues, SG&A decreased to 27.4% from 34.3%

· R&D expense decreased 6.4% to $248,000 from $265,000

· Income before taxes from continuing operations increased 24.8% to $1.572 million from $1.260 million

· Provision for income taxes increased 21.3% to $0.511 million from $0.421 million

· Net income from continuing operations increased 26.5% to $1.062 million from $0.839 million

· Diluted earnings per share increased to $0.06 from $0.05 in 2QFY12

· Cash at the end of the second fiscal quarter was $9.75 million after dividend distributions

o Approximately $796,000 was distributed in November 2012

o Approximately $2,243,000 was distributed in December 2012

o Cash as of April 5 was $10.4 million

· Shareholders’ equity at the end of the quarter was $13.921 million

o This is a decrease of $1.505 million from the end of 2QFY12

o This decrease was after dividend distributions of approximately $5.4 million during calendar 2012

For the first six months of fiscal year 2013 (6moFY13) compared to the first six months of FY2012 (6moFY12):

· Net sales increased 7.4% to a new midyear record $5.408 million from $5.037 million

· Gross profit increased 5.5% to $4.523 million from $4.288 million

· SG&A increased 7.8% to $1.786 million from $1.656 million

· As a percent of revenues, SG&A increased to 33.0% from 32.9%

· R&D expenditures decreased 17.2% to $428,000 from $517,000

1

o Completion of the Company's malaria NCE project reduced R&D expenditures in the current year

· Income before taxes increased 6.2% to $2.468 million from $2.323 million

· Provision for income taxes increased 12.3% to $0.819 million from $0.729 million

· Net income from continuing operations increased 3.4% to $1.649 million from $1.594 million

· For 6moFY13, earnings per share from continuing operations was the same at $0.10 per share.

· Including the $0.216 million net proceeds from the sale of the former Words+ subsidiary last year, net income for 6moFY12 was $1.810 million

· Including the $0.216 million net proceeds from the sale of the former Words+ subsidiary last year, total diluted earnings per share for 6moFY12 was $0.11

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “We continued to exhibit the strong leverage in our business model as each dollar of incremental revenues added approximately $0.80 to operating profit. Record revenue up nearly 12% for the quarter delivered a 26.5% improvement in net income despite an increase in tax rates. After distributing cash dividends of over $5 million to our shareholders during calendar 2012, our cash position remains strong, and we continue to have no debt.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “The second quarter continues our trend of new quarterly records each fiscal quarter, and this quarter is also a record for any quarter. We added 18 new customers, had 93% renewals, and increased our collaboration funding by over $111,000, while consulting revenues decreased by 27%. Results from two recent GastroPlus™ simulation contract studies were submitted to U.S. and European regulatory agencies in support of our customers, making a total of four such submittals in recent months. The acceptance of simulation results in support of regulatory applications has been increasing and we believe is a leading indicator for increased use of simulation and modeling software in the pharmaceutical industry to reduce the time and cost of unnecessary clinical trials.”

The Company has announced an investor conference call that will be webcast live at 1:30 PDT/4:30 PM EDT today, Wednesday, April 10, 2013, which may be accessed by registering here. Upon registering, you will receive a confirmation e-mail with a unique link and instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (646) 307-1720, and enter access code 951-402-096.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

--Tables follow --

2

SIMULATIONS PLUS, INC. CONDENSED BALANCE SHEETS

at February 28, 2013 (Unaudited) and August 31, 2012 (Audited)

ASSETS
	February 28,		August 31,
	2013		2012
Current assets
Cash and cash equivalents	$	9,754,861	$	12,701,075
Income tax refund receivable		2,650		153,896
Accounts receivable, net of allowance for doubtful accounts of $0		2,535,816		1,451,864
Contracts receivable		86,995		18,893
Prepaid expenses and other current assets		168,351		150,856
Deferred income taxes		210,456		193,712
Total current assets		12,759,129		14,670,296
Long-term assets
Capitalized computer software development costs,
net of accumulated amortization of $5,443,703 and $5,084,691		2,702,535		2,479,468
Property and equipment, net		94,091		107,410
Intellectual property, net of accumulated amortization of $7,500 and $3,750		67,500		71,250
Other assets		18,445		18,445
Total assets	$	15,641,700	$	17,346,869
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable	$	254,737	$	177,509
Accrued payroll and other expenses		308,592		312,912
Accrued bonuses to officer		30,000		60,000
Accrued income taxes		27,859		733,233
Deferred revenue		222,735		131,782
Total current liabilities		843,923		1,415,436
Long-term liabilities
Deferred income taxes		876,968		788,857
Total liabilities		1,720,891		2,204,293
Commitments and contingencies
Shareholders' equity
Preferred stock, $0.001 par value
10,000,000 shares authorized
no shares issued and outstanding		–		–
Common stock, $0.001 par value
50,000,000 shares authorized
16,021,309 and 15,923,019 shares issued and outstanding		4,493		4,399
Additional paid-in capital		4,797,317		4,628,366
Retained earnings		9,118,999		10,509,811
Total shareholders' equity		13,920,809		15,142,576
Total liabilities and shareholders' equity	$	15,641,700	$	17,346,869

3

SIMULATIONS PLUS, INC. CONDENSED STATEMENTS OF OPERATIONS

For the three and six months ended February 28 and 29,

(Unaudited)

	Three months ended						Six months ended
	2013			2012			2013			2012
Net sales	$	3,118,121		$	2,789,226		$	5,408,215		$	5,037,182
Cost of sales		498,778			396,566			885,648			748,936
Gross profit		2,619,343			2,392,660			4,522,567			4,288,246
Operating expenses
Selling, general, and administrative		854,983			956,325			1,786,043			1,656,438
Research and development		247,522			264,581			427,857			516,516
Total operating expenses		1,102,505			1,220,906			2,213,900			2,172,954
Income from operations		1,516,838			1,171,754			2,308,667			2,115,292
Other income (expense)
Interest income		17,074			25,083			30,802			46,956
Interest expense		–			–			–			(3	)
Miscellaneous income		15,390			22,656			30,794			22,656
Gain on currency exchange		22,988			40,502			97,642			138,888
Gain (loss) from sale of assets		–			(433	)		–			(433	)
Total other income (expense)		55,452			87,808			159,238			208,064
Income from continuing operations before
provision for income taxes		1,572,290			1,259,562			2,467,905			2,323,356
Provision for income taxes		(510,715	)		(420,985	)		(819,344	)		(729,680	)
Income from continuing operations		1,061,575			838,577			1,648,561			1,593,676
Discontinued operations:
Gain (loss) from discontinued operations, net of tax		–			–			–			(249,898	)
Gain on sale of Words+, net of tax		–			–			–			465,820
Results of discontinued operations		–			–			–			215,922
Net Income	$	1,061,575		$	838,577		$	1,648,561		$	1,809,598
Basic earnings per share:
Continuing operations	$	0.07		$	0.05		$	0.10		$	0.10
Discontinued operations		–			–			–			0.01
Net basic earning per share	$	0.07		$	0.05		$	0.10		$	0.11
Diluted earnings per share
Continuing operations	$	0.06		$	0.05		$	0.10		$	0.10
Discontinued operations		–			–			–			0.01
Net basic earning per share	$	0.06		$	0.05		$	0.10		$	0.11
Weighted-average common shares outstanding
Basic		16,004,397			15,635,898			15,965,890			15,604,420
Diluted		16,336,353			15,995,226			16,305,235			15,957,657

4

EX-99.2

Exhibit 99.2

Simulations Plus, Inc. (NASDAQ:SLP) Second Quarter Fiscal Year 2013 Conference Call and Webinar April 10, 2013

With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: continuing demand for the Company’s products, competitive factors, the Company’s ability to finance future growth, the Company’s ability to produce and market new products in a timely fashion, the Company’s ability to continue to attract and retain skilled personnel, and the Company’s ability to sustain or improve current levels of productivity. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports and filed with the Securities and Exchange Commission. Safe Harbor Statement

• 2 Q13 compared to 2Q12: – 22nd consecutive profitable quarter, and 44 th of last 46 quarters – Sales up 11.8% to Record for any Quarter $3.118 million from $2.789 million – Gross profit up 9.5% to $2.619 million from $2.393 million – SG&A decreased 10.6% to $0.855 million from $0.956 million • As a percent of revenues, SG&A decreased to 27.4% from 34.3% – R&D expense decreased 6.4% to $0.248 million from $0.265 million • 2Q12 included R&D expenditures for malaria NCE project – Net Income increased 26.5% to $1.061 million from $0.839 million – Diluted earnings per share increased 20% to $0.06 from $0.05 – Advance cash dividend of $0.14/share was distributed during 2Q13 ($2.24 million) • Strong balance sheet: – Cash of $9.75 million at 2/28/13 after approximately $5.4M in dividends ( ttm ) • Cash as of April 5 = $10.4 million – Shareholders’ equity on February 28 = $13.921 million – We continue to have no debt SLP 2Q13 Highlights Three months ended 2/28/13:

Income Statement 2QFY13 vs 2QFY12 ($ millions) 2Q13 2Q12 Net sales 3.118 2.789 Gross profit 2.619 2.393 Gross profit margin 84.0% 85.8% SG&A 0.855 0.956 R&D 0.248 0265 Total operating expenses 1.103 1.221 Income from continuing operations 1.517 1.172 Other income 0.055 0.088 Income from discontinued operations 0 0 Income from continuing operations before income taxes 1.572 1.260 Net income 1.061 0.839 Earnings per share 0.065 0.052

Revenues by Quarter (pro forma prior to 2012) $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $2.2 $2.8 $2.8 $1.6 $2.3 $3.1 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013

Gross Profit by Fiscal Quarter (pro forma prior to 2012) $1.24 $1.53 $1.75 $0.71 $1.45 $1.93 $1.97 $1.07 $1.70 $2.21 $2.21 $1.12 $1.90 $2.39 $2.33 $1.32 $1.90 $2.62 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013

EBITDA by Fiscal Quarter $0.55 $0.73 $0.93 $0.20 $0.73 $1.28 $1.23 $0.36 $1.00 $1.48 $1.48 $0.33 $1.11 $1.33 $1.40 $0.55 $1.09 $1.57 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013

Net Income by Quarter (pro forma prior to 2012) $0.33 $0.47 $0.53 $0.17 $0.44 $0.85 $0.74 $0.21 $0.56 $0.91 $1.05 $0.17 $0.76 $0.84 $0.87 $0.35 $0.59 $1.06 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013

New Customers by Quarter 10 11 9 9 14 17 12 14 15 21 13 10 18 18 Q1 Q2 Q3 Q4 2010 2011 2012 2013

Selected Balance Sheet Items ($ millions) February 28, 2013 August 31, 2012 Cash and cash equivalents $9.755 $12.701 Cash per share 0.60 0.79 Total current assets 12.759 14.670 Total assets 15.642 17.347 Total current liabilities 0.844 1.415 Total liabilities 1.721 2.204 Current ratio 15.1 10.4 Shareholders’ equity 13.921 15.143 Total liabilities and shareholders’ equity 15.642 17.347 Shareholders’ equity per diluted share 0.854 0.939

$1.59 $0.80 $0.80 $2.24 $0.00 $0.00 $1.97 $12.66 $13.24 $12.89 $12.70 $11.38 $9.33 $9.76 $10.60 Q4FY11 Q1FY12 Q2FY12 Q3FY12 Q4FY12 Q1FY13 Q2FY13 10-Apr-13 $ Millions Dividend Paid Proceeds from Sale of Subsidiary Cash Returning Cash to Shareholders

N H O OH O CH 3 CH 3 CH 3 Discovery Preclinical Clinical MedChem Studio™ MedChem Designer™ GastroPlus™ DDDPlus™ ADMET Predictor™ Simulations Plus Products & Services Consulting Services & Collaborations MembranePlus ™

Product News • Version 8.5 in final testing – release expected April 2013 • Unique precipitation model added • Infant PBPK physiologies added – pediatrics is high - interest area in FDA and industry • Added a built - in method for transporter in vitro - in vivo extrapolation • Added a number of additional built - in enzyme expression levels • Version 6.5 in final testing – release expected April 2013 • Significantly improved and expanded metabolism predictions • New model of skin permeability and air/water partition coefficient • New much - improved mutagenicity models in Toxicity Module • New licensing software incorporated for greater flexibility and efficiency • Version 3.1 & MedChem Designer 2.0 – release expected April 2013 • Improved molecule depictions • New licensing software • New ultra - fast screening methods for large molecular libraries • New 64 - bit versions offered for screening very large libraries • Version 4.0 • Virtual Trials added to show expected variances in experiments • Adding ADMET Predictor optional module as in GastroPlus • Customer base continues to grow • MembranePlus - coming soon • Explores mechanisms of permeability through cell layers • Explore and understand the effects of experimental setup that affect results • Obtain drug - specific parameters needed for GastroPlus simulations • Analysis of expensive in vitro assays

Marketing and Sales Program • Conferences /Scientific Meetings continue to be primary source of leads • During Q2 we did 5 conferences in the U.S . and Europe • We presented one scientific poster • Trainings and Workshops • Hosted 3 - day GastroPlus workshop at the FDA for over 30 scientists • Conducted 10 on - site training courses at client sites • Held first Cheminformatics training workshop in March (Q3) in Boston/Cambridge • A GastroPlus introductory workshop was held during the same week with an overflow crowd • Strategic Digital Marketing Initiatives continue • Held two webinars on our Cheminformatics software – over 300 registrations • LinkedIn, Facebook, Twitter • Web site redesign in progress • Collaborations/Consulting/Grants – Ongoing 5 - year collaboration with the FDA Center for Food Safety and Applied Nutrition to build toxicity models with ADMET Predictor/Modeler™ for food additives and contaminants – Consulting studies continue – provides exposure of software to new groups – Ongoing funded collaboration for enhancement of the GastroPlus oral cavity dosing model – Ongoing funded collaboration to incorporate transdermal dosing into GastroPlus • We believe fundamental industry shift continues – Received feedback that two more regulatory submissions with GastroPlus modeling results were accepted – 18 new customers during 2QFY13 (includes new companies as well as new departments within existing large customers)

FDA Food Safety Research Collaboration • Completed the first year of a 5 - year renewable Research Collaboration Agreement (RCA) with Center for Food Safety and Applied Nutrition (CFSAN) to provide model - building capabilities for a large number (>70,000) of substances that can be in foods as additives or contaminants, only a small fraction of which have been tested for various toxicities. • Models will then be used to predict the likely toxicity of the molecules that were not tested to identify likely problems • Requested code modifications from the FDA became a part of ADMET Predictor 6.0, which was released in May. • The first new toxicity model for ADMET Predictor coming from this collaboration was released with Version 6.0. This is a model for predicting rodent carcinogenicity. Others are in progress.

NCE (New Chemical Entity) Project • Highly successful malaria NCE project demonstrated the value of Simulations Plus software and consulting services for new molecule design • Seven molecules were received from synthesis and were tested against the malaria parasite. All seven showed inhibition of the growth of the parasite, with two active at a nanomolar level against both wild - type and drug - resistant strains of the parasite . • Although we were not selected for one of the Gates Foundation Challenge grants, communications with outside organizations that are known to fund developments for malaria and other diseases are continuing. • Selection of a second disease target for another NCE design demonstration is ongoing between other tasks. Considerable study has gone into several potential targets. The one currently under examination is looking promising and if it works out, we expect to design new molecules and issue Requests for Quotation for synthesis and testing of a number of new molecules.

Summary • For 2QFY13: - Record financial performance continues our 5 - year - plus profitable trend - Earnings growth 26.5% on 11.8% revenue growth demonstrates high margins • Continuing to Expand our Life Sciences team: - One new IT engineer hired and one new Ph.D. to start in May, another in October - Interviewing additional scientists now, expect further staff expansions in coming months - Additional staff will support expanded product line and greater consulting capacity - Life Sciences team strengthens and supports marketing and sales • Aggressive Marketing and Sales Activities - Greater staff time spent on marketing and sales activities - New training workshop for chemistry tools was held in Boston in March (Q3) - GastroPlus introductory workshop was held in San Diego in April (Q3) - GastroPlus basic training workshop in planning for Japan • Simulations Plus is globally recognized as a leader - Outstanding reputation for scientific expertise and innovation - Known for strong customer support • Strong cash position and no debt - Four quarterly cash dividends of $0.05/share/quarter and one accelerated dividend of $0.14/share were distributed during calendar 2012 for a total of over $5.4 million, yet cash remains at ~$10.6 million as of today. The Board of Directors is scheduled to vote on the potential May distribution at their April 25 meeting.

Q&A